Replimune Group (REPL) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
9 Jul, 2026Opening remarks and agenda
Meeting commenced with a welcome and introduction of the Executive Chairman and key legal and accounting representatives.
Legal formalities were addressed to ensure the meeting was duly authorized.
The Inspector of Elections was introduced and took charge of proxies.
Board and executive committee updates
Directors and officers were introduced, including the CEO, Lead Independent Director, and CFO.
Shareholder proposals
Proposals included the election of five Class I Directors, ratification of the accounting firm, advisory approval of executive compensation, and an amendment to the 2018 Omnibus Incentive Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Replimune Group
- Stockholders will vote on auditor ratification, executive pay, and doubling authorized shares.REPL
Proxy filing13 Jul 2026 - RP1 plus nivolumab achieved a 33.6% ORR and durable responses in anti-PD1 failed melanoma.REPL
Study Result9 Jul 2026 - RP1 shows 34% response in anti-PD-1 failed melanoma, with global launch and expansion planned.REPL
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - FDA accepted RP1 BLA resubmission; cash funds operations into 2027; strong clinical results.REPL
Q4 202629 Jun 2026 - Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress.REPL
Leerink Global Healthcare Conference 20269 Mar 2026 - Net loss rose to $70.9M, FDA review of RP1 advances, and cash runway extends into Q1 2027.REPL
Q3 20263 Feb 2026 - RP1 and RP2 show strong efficacy in tough cancers, with regulatory and commercial progress ongoing.REPL
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Oncolytic immunotherapy nears launch with strong efficacy and broad pipeline expansion.REPL
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Up to $250M in securities, including $100M ATM, to fund late-stage cancer immunotherapy pipeline.REPL
Registration Filing16 Dec 2025